SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | n/a |
| Enterprise Value ($M) | n/a |
| Book Value ($M) | n/a |
| Book Value / Share | n/a |
| Price / Book | n/a |
| NCAV ($M) | 0.00 |
| NCAV / Share | n/a |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Equity (ROE) | n/a |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | n/a |
| Current Ratio | n/a |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | n/a |
| Assets | n/a |
| Liabilities | n/a |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | n/a |
| Operating Income | n/a |
| Net Income | n/a |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | n/a |
| Cash from Investing | n/a |
| Cash from Financing | n/a |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Great Point Partners Llc | 0.00 | -100.00 | |
| 13D/A | Frazier Life Sciences VIII, L.P. | 0.00 | -100.00 | |
| 13D/A | Decheng Capital China Life Sciences USD Fund III, L.P. | 0.00 | -100.00 | |
| 13G/A | BlackRock, Inc. | 4.60 | -1.05 | |
| 13G/A | Lynx1 Capital Management LP | 6.60 | 22.00 | |
| 13G/A | Cormorant Asset Management, LP | 4.39 | -10.53 | |
| 13G/A | Paradigm Biocapital Advisors LP | 5.50 | 37.07 | |
| 13G/A | Omega Fund VI, L.P. | 0.00 | -100.00 | |
| 13G/A | Ra Capital Management, L.p. | 9.99 | 34.24 | |
| 13D/A | Orbimed Advisors Llc | 4.60 | -36.58 | |
| 13D/A | Alpine ImmunoSciences, L.P. | 7.20 | 9.23 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment No. 1 | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Similar Companies | |
|---|---|
| ACET – Adicet Bio, Inc. | ACIU – AC Immune SA |
| ACRV – Acrivon Therapeutics, Inc. | ADMA – ADMA Biologics, Inc. |
| AFMD – Affimed N.V. |
Financial data and stock pages provided by
Fintel.io